OPKO Health (OPK) Financials

$1.14 +0.02 (+1.34%)

As of 12:34 PM Eastern

Annual Income Statements for OPKO Health

This table shows OPKO Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-30	-48	-305	-153	-315	31	-30	-328	-189	-53	-226
Consolidated Net Income / (Loss)	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53	-226
Net Income / (Loss) Continuing Operations	-31	-48	1,443	-153	-315	31	-30	-328	-189	-53	-226
Total Pre-Tax Income	-138	-97	-272	-177	-305	49	-14	-392	-184	-10	-241
Total Operating Income	-98	-97	-276	-171	-274	58	19	-226	-157	-152	-117
Total Gross Profit	256	506	1,129	386	329	541	582	288	318	219	206
Total Revenue	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713	607
Operating Revenue	492	1,117	1,749	990	902	1,435	1,775	1,004	863	713	607
Total Cost of Revenue	235	611	620	605	572	894	1,193	716	545	495	401
Operating Cost of Revenue	235	611	620	605	572	894	1,193	716	545	495	401
Total Operating Expenses	355	603	-344	557	604	483	563	514	475	371	323
Selling, General & Admin Expense	197	407	415	358	343	356	469	373	301	304	223
Research & Development Expense	99	114	126	126	118	75	77	74	90	105	124
Amortization Expense	28	64	71	68	65	56	50	88	86	83	78
Other Special Charges / (Income)	5.05	17	-3.42	-17	-15	-3.99	-33	-20	-1.04	-121	-102
Total Other Income / (Expense), net	-40	-0.27	4.52	-6.07	-31	-9.03	-33	-165	-27	142	-124
Interest Expense	8.42	7.43	6.60	12	22	22	19	12	14	47	108
Interest & Investment Income	0.26	0.48	0.61	1.24	1.71	0.15	0.03	1.98	3.98	8.43	15
Other Income / (Expense), net	-31	6.68	11	4.58	-11	13	-14	-155	-18	181	-30
Income Tax Expense	-114	-56	19	-39	7.06	18	15	-63	4.44	43	-16
Other Gains / (Losses), net	-7.11	-7.65	-14	-14	-2.90	-0.48	-0.63	-0.38	-0.11	-0.02	-0.03
Basic Earnings per Share	($0.06)	($0.09)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)	($0.30)
Weighted Average Basic Shares Outstanding	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	648.08M	719.06M	751.77M	694.02M	751.13M
Diluted Earnings per Share	($0.06)	($0.10)	-	($0.27)	($0.53)	$0.05	-	-	($0.25)	($0.08)	($0.30)
Weighted Average Diluted Shares Outstanding	488.07M	555.61M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	751.77M	694.02M	751.13M
Weighted Average Basic & Diluted Shares Outstanding	488.07M	550.85M	559.16M	563.14M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M	759.07M

This table shows OPKO Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-84	-66	-82	-10	25	14	-68	-148	22	-31	-55
Consolidated Net Income / (Loss)	-84	-66	-82	-10	25	14	-68	-148	22	-31	-55
Net Income / (Loss) Continuing Operations	-84	-66	-82	-10	25	14	-68	-148	22	-31	-55
Total Pre-Tax Income	-78	-72	-83	-11	48	35	-73	-163	41	-47	-61
Total Operating Income	-64	-69	-71	-62	14	-33	-67	-60	48	-38	-51
Total Gross Profit	48	45	42	52	40	85	43	49	50	64	46
Total Revenue	179	182	174	182	174	184	150	157	152	148	124
Operating Revenue	179	182	174	182	174	184	150	157	152	148	124
Total Cost of Revenue	131	137	132	131	134	99	107	107	102	84	78
Operating Cost of Revenue	131	137	132	131	134	99	107	107	102	84	78
Total Operating Expenses	112	114	114	113	26	118	110	109	1.84	102	97
Selling, General & Admin Expense	72	73	70	69	98	67	59	60	54	51	49
Research & Development Expense	19	19	22	24	29	30	31	30	30	33	29
Amortization Expense	22	21	21	20	20	20	20	19	20	19	19
Total Other Income / (Expense), net	-14	-3.45	-12	51	34	68	-6.21	-103	-6.63	-8.59	-9.94
Interest Expense	3.38	3.45	7.69	8.18	17	14	15	70	11	11	11
Interest & Investment Income	0.97	0.91	0.81	0.39	2.93	4.29	4.68	3.29	3.02	3.82	3.01
Other Income / (Expense), net	-12	-0.90	-4.84	59	49	78	4.58	-35	1.71	-1.09	-2.01
Income Tax Expense	6.08	-6.02	-1.35	-0.28	24	21	-5.77	-14	20	-16	-6.11
Other Gains / (Losses), net	-0.02	-0.01	-0.00	-0.00	-0.00	-0.01	-0.01	0.00	-0.00	-0.02	-0.00
Basic Earnings per Share	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01	($0.10)	($0.19)	$0.03	($0.04)	($0.07)
Weighted Average Basic Shares Outstanding	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M	671.58M	788.01M	777.15M	751.13M	758.88M
Diluted Earnings per Share	($0.11)	-	-	($0.01)	$0.03	-	($0.10)	($0.19)	$0.03	-	($0.07)
Weighted Average Diluted Shares Outstanding	751.53M	696.99M	696.99M	697.21M	998.36M	671.55M	671.58M	788.01M	779.92M	751.13M	758.88M
Weighted Average Basic & Diluted Shares Outstanding	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M	793.05M	793.78M	767.70M	759.07M	755.09M

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	97	-25	-77	4.97	-11	-13	62	18	-57	350	-63
Net Cash From Operating Activities	164	32	-92	-109	-173	39	38	-95	-28	-183	-179
Net Cash From Continuing Operating Activities	164	32	-92	-109	-173	39	38	-95	-28	-183	-179
Net Income / (Loss) Continuing Operations	-31	-48	-305	-153	-315	31	-30	-328	-189	-53	-226
Consolidated Net Income / (Loss)	-31	-48	-305	-153	-315	31	-30	-328	-189	-53	-226
Depreciation Expense	42	97	102	97	94	85	79	109	105	98	92
Amortization Expense	1.21	0.24	0.22	0.19	1.00	0.85	0.79	1.16	1.22	1.97	5.23
Non-Cash Adjustments To Reconcile Net Income	66	1.61	-9.30	57	58	0.07	-13	159	32	-273	6.63
Changes in Operating Assets and Liabilities, net	86	-18	120	-110	-9.96	-77	1.54	-35	22	43	-56
Net Cash From Investing Activities	-99	-21	-47	-26	-13	-18	36	91	-18	352	230
Net Cash From Continuing Investing Activities	-99	-21	-47	-26	-13	-18	36	91	-18	352	230
Purchase of Property, Plant & Equipment	-11	-19	-47	-28	-13	-34	-32	-25	-16	-25	-12
Acquisitions	-84	-5.00	-	-	0.00	0.00	-4.00	-1.76	0.00	0.00	0.00
Purchase of Investments	-4.38	-30	-9.63	-1.00	-1.20	0.00	-2.00	0.00	-5.00	0.00	-7.67
Sale of Property, Plant & Equipment	0.00	1.40	7.27	1.22	0.67	0.25	66	1.95	2.71	0.24	0.29
Divestitures	-	16	-	-	-	-	-	0.00	0.00	210	198
Sale and/or Maturity of Investments	0.00	16	2.21	1.52	0.00	15	8.08	115	0.36	167	52
Net Cash From Financing Activities	33	-35	61	141	175	-35	-10	23	-11	184	-118
Net Cash From Continuing Financing Activities	33	-35	61	141	175	-35	-10	23	-11	184	-118
Repayment of Debt	-254	-66	-34	-35	-396	-1,144	-1,696	-1,036	-680	-519	-104
Repurchase of Common Equity	-	-	-	-	-	-	-	0.00	0.00	-90	-47
Issuance of Debt	261	22	92	82	495	1,108	1,685	1,060	672	939	33
Other Financing Activities, net	-	-	2.13	1.17	-0.00	0.76	1.08	-0.77	-3.27	-146	-0.43
Effect of Exchange Rate Changes	-1.12	-1.01	0.47	-	-0.48	0.69	-1.44	-0.34	0.39	-3.16	3.43
Cash Interest Paid	4.57	2.89	1.31	2.08	12	11	8.52	7.42	8.14	21	38
Cash Income Taxes Paid	4.88	-27	5.42	-1.41	2.67	-0.90	5.97	8.04	3.71	10	24

This table details how cash moves in and out of OPKO Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	31	-43	-20	-35	379	26	4.06	-168	147	-46	-27
Net Cash From Operating Activities	33	-38	-36	-26	-77	-44	-35	-83	-35	-26	-19
Net Cash From Continuing Operating Activities	33	-38	-36	-26	-77	-44	-35	-83	-35	-26	-19
Net Income / (Loss) Continuing Operations	-84	-66	-82	-10	25	14	-68	-148	22	-31	-55
Consolidated Net Income / (Loss)	-84	-66	-82	-10	25	14	-68	-148	22	-31	-55
Depreciation Expense	26	26	26	24	24	24	23	23	23	22	22
Amortization Expense	0.31	0.31	0.52	0.43	0.38	0.65	0.43	4.53	0.14	0.14	0.14
Non-Cash Adjustments To Reconcile Net Income	12	6.80	9.62	-50	-120	-111	5.23	90	-98	9.95	9.20
Changes in Operating Assets and Liabilities, net	79	-4.91	10	8.81	-6.33	28	3.92	-52	19	-27	4.00
Net Cash From Investing Activities	-3.57	-1.42	-4.40	-7.16	248	116	41	-2.83	195	-2.05	-1.80
Net Cash From Continuing Investing Activities	-3.57	-1.42	-4.40	-7.16	248	116	41	-2.83	195	-2.05	-1.80
Purchase of Property, Plant & Equipment	-4.20	-3.02	-4.44	-7.22	-7.94	-5.41	-3.19	-3.28	-3.14	-2.67	-1.83
Purchase of Investments	-	-	0.00	-	-1.45	1.45	-8.00	0.34	-	-	0.00
Sale of Property, Plant & Equipment	-	1.60	0.05	-	-	0.07	0.07	0.11	198	-198	0.03
Sale and/or Maturity of Investments	-0.48	-	0.00	0.06	47	120	52	-	-	0.53	0.00
Net Cash From Financing Activities	2.11	-3.75	21	-2.12	206	-40	-4.02	-79	-16	-18	-5.16
Net Cash From Continuing Financing Activities	2.11	-3.75	21	-2.12	206	-40	-4.02	-79	-16	-18	-5.16
Repayment of Debt	-171	-160	-323	-156	-151	-35	-9.55	-9.67	-71	-13	-8.88
Repurchase of Common Equity	-	-	-50	-	-24	-16	0.00	-18	-15	-14	-4.77
Issuance of Debt	173	156	394	154	381	11	5.61	11	7.87	8.53	8.49
Other Financing Activities, net	0.03	0.00	0.00	-	-	-	-0.09	-62	62	-0.13	0.00
Effect of Exchange Rate Changes	-1.13	0.72	-0.89	0.65	2.64	-5.56	2.11	-	-	0.17	-0.91
Cash Interest Paid	6.54	-2.61	3.13	0.39	9.47	7.90	14	6.31	10	7.73	9.60
Cash Income Taxes Paid	-1.51	4.54	1.06	0.51	2.23	6.21	2.06	18	0.76	3.84	-2.57

This table presents OPKO Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200	1,932
Total Current Assets	454	484	349	318	324	523	823	395	309	662	582
Cash & Equivalents	194	169	91	96	85	72	135	153	-	432	369
Accounts Receivable	194	220	166	144	135	286	260	127	123	118	90
Inventories, net	40	47	49	42	53	132	87	74	66	57	66
Prepaid Expenses	27	47	43	35	51	32	27	40	25	55	57
Plant, Property, & Equipment, net	132	123	147	145	0.00	141	80	83	75	70	74
Total Noncurrent Assets	2,213	2,160	2,095	1,989	1,985	1,809	1,497	1,690	1,627	1,468	1,276
Long-Term Investments	35	41	41	31	21	16	11	28	16	55	14
Goodwill	743	705	717	700	672	681	521	596	598	529	484
Intangible Assets	1,430	1,409	1,331	1,250	529	1,065	912	1,019	935	617	711
Other Noncurrent Operating Assets	4.84	5.76	5.62	7.22	764	48	54	47	77	268	66
Total Liabilities & Shareholders' Equity	2,799	2,767	2,590	2,451	2,309	2,473	2,400	2,167	2,012	2,200	1,932
Total Liabilities	819	675	746	660	695	802	715	606	622	835	664
Total Current Liabilities	252	263	312	288	249	375	330	213	200	193	147
Short-Term Debt	11	12	12	37	9.62	-	15	37	27	15	10
Accounts Payable	73	53	74	47	63	101	82	67	70	47	41
Accrued Expenses	168	198	226	204	165	241	193	98	90	118	84
Other Current Liabilities	-	-	-	-	12	34	12	12	13	13	11
Total Noncurrent Liabilities	567	412	434	371	445	426	385	392	422	642	517
Long-Term Debt	49	44	29	57	211	222	188	210	214	419	331
Noncurrent Deferred & Payable Income Tax Liabilities	226	165	149	115	119	137	148	126	127	141	126
Other Noncurrent Operating Liabilities	292	202	256	199	115	67	48	55	81	82	60
Total Equity & Noncontrolling Interests	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365	1,268
Total Preferred & Common Equity	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365	1,268
Total Common Equity	1,980	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365	1,268
Common Stock	2,711	2,851	2,895	3,010	3,150	3,159	3,229	3,430	3,441	3,488	3,583
Retained Earnings	-705	-730	-1,049	-1,197	-1,511	-1,482	-1,512	-1,823	-2,012	-2,065	-2,291
Treasury Stock	-3.65	-1.91	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-3.18
Accumulated Other Comprehensive Income / (Loss)	-23	-27	-0.53	-20	-22	-4.23	-30	-43	-38	-56	-21

This table presents OPKO Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	2,225	2,170	2,159	2,057	1,974	1,980	2,256	2,128	1,973	1,996	1,857
Total Current Assets	414	406	434	357	391	358	630	738	583	627	535
Restricted Cash	-	-	-	-	-	-	-	-	-	-	342
Accounts Receivable	123	121	211	117	111	105	107	96	99	95	80
Inventories, net	71	75	74	69	59	60	59	64	66	65	64
Prepaid Expenses	39	99	41	32	25	32	57	54	59	52	49
Plant, Property, & Equipment, net	0.00	81	79	78	64	67	72	71	75	75	73
Total Noncurrent Assets	1,811	1,487	1,646	1,621	1,519	1,555	1,554	1,320	1,315	1,293	1,249
Long-Term Investments	78	41	28	19	41	101	101	13	13	13	11
Goodwill	573	597	597	594	531	530	536	477	484	484	482
Intangible Assets	835	804	782	953	875	854	836	569	751	730	691
Other Noncurrent Operating Assets	324	45	239	54	72	69	81	262	67	66	65
Total Liabilities & Shareholders' Equity	2,225	2,170	2,159	2,057	1,974	1,980	2,256	2,128	1,973	1,996	1,857
Total Liabilities	596	618	624	612	721	585	853	817	676	690	652
Total Current Liabilities	267	222	226	201	204	220	212	296	171	169	148
Short-Term Debt	94	24	29	30	23	22	13	113	14	13	9.65
Accounts Payable	50	81	88	67	71	82	63	59	57	51	44
Accrued Expenses	112	106	99	92	89	95	123	113	91	96	83
Other Current Liabilities	12	11	11	11	12	12	13	9.89	9.92	10	11
Total Noncurrent Liabilities	328	395	397	412	517	365	641	521	505	521	504
Long-Term Debt	142	211	212	213	323	176	424	323	326	329	334
Noncurrent Deferred & Payable Income Tax Liabilities	135	130	133	138	122	119	128	129	113	130	115
Other Noncurrent Operating Liabilities	52	54	52	60	72	70	89	68	65	61	55
Total Equity & Noncontrolling Interests	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297	1,305	1,205
Total Preferred & Common Equity	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297	1,305	1,205
Total Common Equity	1,629	1,552	1,535	1,445	1,253	1,395	1,403	1,312	1,297	1,305	1,205
Common Stock	3,427	3,432	3,435	3,438	3,393	3,548	3,524	3,491	3,604	3,593	3,579
Retained Earnings	-1,738	-1,841	-1,861	-1,945	-2,094	-2,104	-2,079	-2,133	-2,281	-2,259	-2,346
Treasury Stock	-	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-1.79	-2.39	-1.79
Accumulated Other Comprehensive Income / (Loss)	-58	-38	-37	-46	-45	-47	-40	-45	-25	-25	-27

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	439.49%	127.25%	56.49%	-43.37%	-8.92%	59.15%	23.64%	-43.42%	-14.01%	-17.41%	-14.90%
EBITDA Growth	39.43%	108.04%	-2,456.56%	57.77%	-175.53%	182.31%	-46.18%	-422.11%	74.86%	288.68%	-139.47%
EBIT Growth	18.62%	30.78%	-195.91%	37.35%	-71.14%	124.71%	-93.15%	-8,002.34%	54.18%	116.41%	-615.09%
NOPAT Growth	32.46%	1.96%	-186.32%	38.07%	-60.08%	119.20%	-64.36%	-1,306.68%	30.60%	3.16%	22.79%
Net Income Growth	82.00%	-53.87%	3,084.90%	-110.60%	-105.78%	109.71%	-198.55%	-989.49%	42.49%	71.82%	-324.02%
EPS Growth	85.37%	-66.67%	0.00%	0.00%	-96.30%	109.43%	0.00%	0.00%	0.00%	0.00%	-275.00%
Operating Cash Flow Growth	281.48%	-80.46%	-387.34%	-18.53%	-58.07%	122.88%	-2.89%	-348.30%	70.38%	-550.74%	2.70%
Free Cash Flow Firm Growth	-339.41%	89.72%	95.62%	-1,384.41%	-29.74%	75.83%	222.52%	-131.59%	90.48%	6,944.94%	-95.45%
Invested Capital Growth	0.00%	6.94%	-9.55%	0.33%	-1.64%	4.41%	-1.95%	-8.08%	-6.67%	-13.55%	-6.60%
Revenue Q/Q Growth	103.95%	-8.58%	79.11%	-42.16%	0.28%	23.20%	-5.00%	-17.70%	-0.40%	0.24%	-5.48%
EBITDA Q/Q Growth	35.96%	-85.49%	-111.08%	42.98%	-3.00%	3,140.41%	-57.43%	-12.94%	30.25%	727.88%	-242.59%
EBIT Q/Q Growth	18.79%	-90.64%	-49.08%	24.35%	-1.65%	183.79%	-95.90%	-11.23%	14.68%	133.27%	-133.09%
NOPAT Q/Q Growth	19.93%	-213.38%	-43.62%	28.31%	-8.92%	150.54%	-87.16%	3.34%	-9.62%	19.10%	-4.61%
Net Income Q/Q Growth	63.66%	-392.50%	1,261.53%	-110.53%	-13.02%	126.82%	-139.70%	-3.61%	9.03%	60.20%	-25.10%
EPS Q/Q Growth	80.00%	-225.00%	0.00%	0.00%	-10.42%	127.78%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	10.37%	521.05%	-44.14%	-50.81%	-7.06%	196.71%	-51.00%	-37.53%	-31.01%	-3.45%	9.38%
Free Cash Flow Firm Q/Q Growth	-77.14%	-21.01%	94.45%	-431.19%	-0.90%	59.18%	-52.51%	-142.83%	93.96%	53.85%	-87.67%
Invested Capital Q/Q Growth	-1.81%	-2.31%	-12.42%	-2.10%	-2.92%	0.03%	-1.95%	1.32%	-0.73%	-1.55%	0.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.16%	45.28%	64.54%	38.94%	36.53%	37.69%	32.77%	28.70%	36.84%	30.64%	33.93%
EBITDA Margin	-17.57%	0.62%	-9.36%	-6.98%	-21.11%	10.91%	4.75%	-27.05%	-7.91%	18.06%	-8.38%
Operating Margin	-20.03%	-8.64%	-15.81%	-17.29%	-30.38%	4.02%	1.06%	-22.53%	-18.18%	-21.32%	-19.35%
EBIT Margin	-26.40%	-8.04%	-15.21%	-16.83%	-31.62%	4.91%	0.27%	-37.99%	-20.24%	4.02%	-24.34%
Profit (Net Income) Margin	-6.39%	-4.33%	82.54%	-15.45%	-34.92%	2.13%	-1.70%	-32.70%	-21.87%	-7.46%	-37.19%
Tax Burden Percent	22.77%	49.95%	-530.83%	86.33%	103.27%	62.83%	214.92%	83.88%	102.47%	513.65%	93.50%
Interest Burden Percent	106.29%	107.74%	102.25%	106.39%	106.95%	69.09%	-290.55%	102.64%	105.45%	-36.13%	163.40%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	36.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.61%	-3.61%	-10.49%	-6.83%	-11.00%	2.08%	0.73%	-9.32%	-6.99%	-7.52%	-6.47%
ROIC Less NNEP Spread (ROIC-NNEP)	-52.30%	-15.55%	-1,345.46%	46.71%	-312.54%	-2.94%	-38.71%	-234.47%	-87.82%	130.12%	299.30%
Return on Net Nonoperating Assets (RNNOA)	4.43%	1.23%	83.85%	-1.59%	-7.49%	-0.22%	-2.53%	-10.91%	-5.81%	3.65%	-10.67%
Return on Equity (ROE)	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%	-17.14%
Cash Return on Invested Capital (CROIC)	-207.61%	-10.31%	-0.46%	-7.15%	-9.34%	-2.23%	2.70%	-0.90%	-0.09%	7.01%	0.36%
Operating Return on Assets (OROA)	-9.28%	-3.23%	-9.93%	-6.61%	-11.98%	2.95%	0.20%	-16.70%	-8.37%	1.36%	-7.15%
Return on Assets (ROA)	-2.25%	-1.74%	53.90%	-6.07%	-13.23%	1.28%	-1.24%	-14.38%	-9.04%	-2.53%	-10.92%
Return on Common Equity (ROCE)	-3.17%	-2.38%	73.36%	-8.42%	-18.49%	1.86%	-1.80%	-20.23%	-12.80%	-3.86%	-17.14%
Return on Equity Simple (ROE_SIMPLE)	-1.59%	-2.31%	78.30%	-8.54%	-19.50%	1.83%	-1.79%	-21.03%	-13.59%	-3.90%	0.00%
Net Operating Profit after Tax (NOPAT)	-69	-68	-194	-120	-192	37	13	-158	-110	-106	-82
NOPAT Margin	-14.02%	-6.05%	-11.07%	-12.10%	-21.27%	2.57%	0.74%	-15.77%	-12.73%	-14.93%	-13.54%
Net Nonoperating Expense Percent (NNEP)	44.69%	11.94%	1,334.97%	-53.53%	301.54%	5.02%	39.44%	225.15%	80.83%	-137.64%	-305.77%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-8.76%	-6.74%	-5.91%	-5.11%
Cost of Revenue to Revenue	47.84%	54.72%	35.46%	61.06%	63.47%	62.31%	67.23%	71.30%	63.16%	69.36%	66.07%
SG&A Expenses to Revenue	39.98%	36.45%	23.71%	36.19%	38.06%	24.77%	26.42%	37.11%	34.81%	42.66%	36.75%
R&D to Revenue	20.23%	10.19%	7.23%	12.68%	13.07%	5.25%	4.33%	7.36%	10.38%	14.75%	20.44%
Operating Expenses to Revenue	72.19%	53.92%	-19.65%	56.23%	66.91%	33.67%	31.71%	51.23%	55.03%	51.96%	53.28%
Earnings before Interest and Taxes (EBIT)	-130	-90	-266	-167	-285	70	4.83	-381	-175	29	-148
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-86	6.94	-164	-69	-190	157	84	-272	-68	129	-51
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.77	2.48	1.49	0.94	0.61	1.58	1.94	0.62	0.84	0.73	0.76
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	2.36	0.00	12.97	0.00	0.00	40.81	3.62
Price to Revenue (P/Rev)	11.14	4.64	1.57	1.70	1.08	1.84	1.85	0.96	1.35	1.41	1.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	86.53	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	1.16%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.93	2.60	1.51	0.94	0.63	1.54	1.88	0.63	0.85	0.72	0.75
Enterprise Value to Revenue (EV/Rev)	10.80	4.50	1.52	1.67	1.21	1.94	1.88	1.03	1.50	1.33	1.53
Enterprise Value to EBITDA (EV/EBITDA)	0.00	724.60	0.00	0.00	0.00	17.75	39.54	0.00	0.00	7.38	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	39.46	690.79	0.00	0.00	33.16	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	75.50	254.05	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	32.37	156.99	0.00	0.00	0.00	70.44	86.98	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	69.11	0.00	0.00	9.58	204.74
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.03	0.03	0.02	0.05	0.14	0.13	0.12	0.16	0.17	0.32	0.27
Long-Term Debt to Equity	0.02	0.02	0.02	0.03	0.13	0.13	0.11	0.13	0.15	0.31	0.26
Financial Leverage	-0.08	-0.08	-0.06	-0.03	0.02	0.08	0.07	0.05	0.07	0.03	-0.04
Leverage Ratio	1.41	1.37	1.36	1.39	1.40	1.46	1.45	1.41	1.42	1.53	1.57
Compound Leverage Factor	1.50	1.47	1.39	1.48	1.49	1.01	-4.22	1.44	1.49	-0.55	2.56
Debt to Total Capital	2.96%	2.59%	2.18%	5.02%	12.03%	11.72%	10.73%	13.65%	14.82%	24.13%	21.23%
Short-Term Debt to Total Capital	0.56%	0.56%	0.63%	1.98%	0.52%	0.00%	0.78%	2.02%	1.67%	0.83%	0.64%
Long-Term Debt to Total Capital	2.40%	2.04%	1.55%	3.04%	11.51%	11.72%	9.96%	11.63%	13.14%	23.29%	20.59%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.04%	97.41%	97.82%	94.98%	87.97%	88.28%	89.27%	86.35%	85.18%	75.87%	78.77%
Debt to EBITDA	-0.70	8.02	-0.25	-1.37	-1.16	1.42	2.40	-0.91	-3.54	3.37	-6.72
Net Debt to EBITDA	1.94	-22.21	0.56	0.48	-0.60	0.86	0.68	-0.24	-1.90	-0.41	0.82
Long-Term Debt to EBITDA	-0.57	6.29	-0.18	-0.83	-1.11	1.42	2.23	-0.77	-3.14	3.25	-6.52
Debt to NOPAT	-0.88	-0.82	-0.21	-0.79	-1.15	6.03	15.44	-1.56	-2.20	-4.08	-4.16
Net Debt to NOPAT	2.44	2.28	0.47	0.28	-0.60	3.64	4.36	-0.41	-1.18	0.49	0.51
Long-Term Debt to NOPAT	-0.71	-0.65	-0.15	-0.48	-1.10	6.03	14.32	-1.33	-1.95	-3.94	-4.03
Altman Z-Score	3.77	4.63	1.99	1.04	-0.05	1.89	2.86	-0.24	-0.07	0.03	-0.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.80	1.84	1.12	1.10	1.30	1.39	2.49	1.85	1.55	3.43	3.97
Quick Ratio	1.54	1.48	0.82	0.83	0.88	0.95	1.20	1.31	0.62	2.85	0.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,881	-193	-8.46	-126	-163	-39	48	-15	-1.45	99	4.52
Operating Cash Flow to CapEx	1,512.30%	186.90%	-234.58%	-409.77%	-1,429.35%	118.06%	0.00%	-420.69%	-207.91%	-740.83%	-1,488.97%
Free Cash Flow to Firm to Interest Expense	-223.41	-26.01	-1.28	-10.56	-7.57	-1.80	2.56	-1.26	-0.11	2.09	0.04
Operating Cash Flow to Interest Expense	19.48	4.31	-13.95	-9.18	-8.02	1.80	2.03	-7.90	-2.09	-3.87	-1.65
Operating Cash Flow Less CapEx to Interest Expense	18.19	2.01	-19.90	-11.42	-8.58	0.28	3.82	-9.77	-3.09	-4.39	-1.76
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.40	0.65	0.39	0.38	0.60	0.73	0.44	0.41	0.34	0.29
Accounts Receivable Turnover	0.00	5.40	9.07	6.40	6.48	6.82	6.50	5.19	6.89	5.91	5.83
Inventory Turnover	0.00	14.07	12.84	13.20	11.96	9.63	10.90	8.92	7.80	8.08	6.54
Fixed Asset Turnover	0.00	8.78	12.98	6.80	0.00	0.00	16.11	12.35	10.91	9.80	8.43
Accounts Payable Turnover	0.00	9.71	9.71	9.94	10.42	10.95	13.05	9.61	7.98	8.47	9.09
Days Sales Outstanding (DSO)	0.00	67.64	40.26	57.02	56.36	53.52	56.14	70.32	52.98	61.78	62.63
Days Inventory Outstanding (DIO)	0.00	25.94	28.42	27.66	30.52	37.91	33.47	40.93	46.77	45.20	55.81
Days Payable Outstanding (DPO)	0.00	37.57	37.57	36.73	35.04	33.35	27.98	37.99	45.73	43.08	40.14
Cash Conversion Cycle (CCC)	0.00	56.00	31.11	47.95	51.83	58.08	61.64	73.26	54.02	63.90	78.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,812	1,938	1,753	1,758	1,729	1,806	1,770	1,627	1,519	1,313	1,226
Invested Capital Turnover	0.54	0.60	0.95	0.56	0.52	0.81	0.99	0.59	0.55	0.50	0.48
Increase / (Decrease) in Invested Capital	1,812	126	-185	5.73	-29	76	-35	-143	-108	-206	-87
Enterprise Value (EV)	5,310	5,031	2,650	1,652	1,093	2,781	3,334	1,032	1,297	951	926
Market Capitalization	5,477	5,185	2,741	1,685	978	2,647	3,277	966	1,167	1,003	967
Book Value per Share	$3.63	$3.75	$3.30	$3.20	$2.43	$2.49	$2.47	$2.02	$1.80	$2.00	$1.65
Tangible Book Value per Share	($0.36)	($0.04)	($0.37)	($0.28)	$0.62	($0.11)	$0.37	($0.07)	($0.19)	$0.04	$0.35
Total Capital	2,040	2,147	1,885	1,886	1,836	1,894	1,888	1,809	1,631	1,800	1,610
Total Debt	60	56	41	95	221	222	203	247	242	434	342
Total Long-Term Debt	49	44	29	57	211	222	188	210	214	419	331
Net Debt	-168	-154	-91	-33	115	134	57	66	130	-52	-42
Capital Expenditures (CapEx)	11	17	39	27	12	33	-34	23	14	25	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	20	64	-43	-30	-0.91	75	373	64	41	52	76
Debt-free Net Working Capital (DFNWC)	214	232	49	67	85	148	508	218	137	484	445
Net Working Capital (NWC)	202	220	37	29	75	148	493	181	109	469	435
Net Nonoperating Expense (NNE)	-38	-19	-1,637	33	123	6.24	43	170	79	-53	143
Net Nonoperating Obligations (NNO)	-168	-154	-91	-33	115	134	85	66	130	-52	-42
Total Depreciation and Amortization (D&A)	43	97	102	98	95	86	80	110	107	100	97
Debt-free, Cash-free Net Working Capital to Revenue	4.07%	5.69%	-2.44%	-2.99%	-0.10%	5.26%	21.02%	6.42%	4.73%	7.30%	12.59%
Debt-free Net Working Capital to Revenue	43.44%	20.79%	2.79%	6.75%	9.37%	10.29%	28.61%	21.67%	15.83%	67.87%	73.40%
Net Working Capital to Revenue	41.11%	19.71%	2.11%	2.97%	8.31%	10.29%	27.78%	18.03%	12.67%	65.76%	71.71%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	($0.25)	($0.08)	($0.30)
Adjusted Weighted Average Basic Shares Outstanding	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	751.77M	694.02M	751.13M
Adjusted Diluted Earnings per Share	($0.06)	($0.05)	($0.55)	($0.27)	($0.53)	$0.05	($0.05)	($0.46)	$0.00	$0.00	($0.30)
Adjusted Weighted Average Diluted Shares Outstanding	545.70M	558.22M	559.47M	563.14M	669.83M	670.04M	648.08M	719.06M	696.99M	671.55M	751.13M
Adjusted Basic & Diluted Earnings per Share	($0.06)	($0.05)	($0.55)	$0.00	($0.53)	$0.05	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	488.07M	550.85M	559.16M	615.60M	595.45M	640.66M	681.46M	772.65M	696.99M	671.55M	759.07M
Normalized Net Operating Profit after Tax (NOPAT)	-65	-56	-187	-116	-138	34	-10	-172	-111	-191	-153
Normalized NOPAT Margin	-13.30%	-4.99%	-10.67%	-11.75%	-15.25%	2.39%	-0.57%	-17.16%	-12.81%	-26.85%	-25.26%
Pre Tax Income Margin	-28.06%	-8.66%	-15.55%	-17.90%	-33.81%	3.39%	-0.79%	-38.99%	-21.35%	-1.45%	-39.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-15.42	-12.10	-40.29	-14.01	-13.25	3.21	0.26	-31.64	-12.94	0.60	-1.36
NOPAT to Interest Expense	-8.19	-9.10	-29.32	-10.08	-8.92	1.68	0.70	-13.14	-8.14	-2.24	-0.76
EBIT Less CapEx to Interest Expense	-16.71	-14.40	-46.23	-16.25	-13.81	1.69	2.05	-33.52	-13.95	0.08	-1.47
NOPAT Less CapEx to Interest Expense	-9.48	-11.40	-35.26	-12.32	-9.48	0.15	2.49	-15.01	-9.14	-2.76	-0.87
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%	-20.84%

This table displays calculated financial ratios and metrics derived from OPKO Health's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	759,067,256.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	759,067,256.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.07
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.64%	-1.85%	-26.89%	-31.36%	-2.78%	0.95%	-13.66%	-13.93%	-12.65%	-19.16%	-17.18%
EBITDA Growth	49.32%	40.42%	-512.78%	72.92%	277.16%	259.49%	22.61%	-411.78%	-16.88%	-124.28%	20.65%
EBIT Growth	38.75%	30.07%	-421.39%	80.39%	182.74%	164.24%	17.98%	-3,316.10%	-20.82%	-187.71%	15.28%
NOPAT Growth	26.66%	-24.92%	-133.61%	-977.86%	116.21%	72.49%	6.02%	2.74%	243.34%	-101.70%	24.05%
Net Income Growth	1.88%	22.00%	-348.00%	47.53%	129.47%	121.10%	17.38%	-1,340.48%	-13.09%	-322.83%	18.88%
EPS Growth	0.00%	0.00%	0.00%	0.00%	127.27%	0.00%	0.00%	-1,800.00%	0.00%	0.00%	30.00%
Operating Cash Flow Growth	202.71%	-21.11%	-57.05%	-7,142.47%	-332.80%	-15.97%	2.85%	-215.57%	55.05%	41.63%	44.12%
Free Cash Flow Firm Growth	-77.42%	-42.43%	-93.70%	4,812.18%	552.94%	220.04%	35.18%	-121.01%	-31.03%	-68.88%	167.37%
Invested Capital Growth	-4.75%	-6.67%	-4.77%	-18.27%	-12.82%	-13.55%	-5.27%	0.89%	-8.64%	-6.60%	-7.96%
Revenue Q/Q Growth	-32.71%	1.85%	-4.52%	4.89%	-4.70%	5.76%	-18.34%	4.57%	-3.28%	-2.12%	-16.34%
EBITDA Q/Q Growth	-491.55%	11.52%	-14.48%	143.60%	301.16%	-20.34%	-155.55%	-75.64%	206.95%	-123.26%	-81.57%
EBIT Q/Q Growth	-433.08%	7.92%	-9.10%	96.34%	2,348.69%	-28.51%	-239.30%	-52.55%	152.12%	-179.19%	-34.54%
NOPAT Q/Q Growth	-1,016.83%	-7.20%	-3.52%	13.71%	116.93%	-281.94%	-253.59%	10.70%	159.77%	-206.89%	-33.15%
Net Income Q/Q Growth	-330.11%	21.30%	-23.09%	87.41%	341.53%	-43.64%	-582.02%	-119.55%	114.57%	-244.50%	-75.47%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	115.79%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	9,170.96%	-215.66%	7.12%	25.67%	-191.58%	42.39%	22.19%	-141.42%	58.47%	25.19%	25.50%
Free Cash Flow Firm Q/Q Growth	672.14%	93.00%	-68.83%	1,269.08%	-20.72%	-5.40%	-86.83%	-312.80%	360.25%	-57.32%	13.12%
Invested Capital Q/Q Growth	-6.74%	-0.73%	-9.69%	-2.26%	-0.51%	-1.55%	-1.05%	4.10%	-9.91%	0.64%	-2.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	26.70%	24.58%	24.22%	28.35%	23.11%	46.10%	28.42%	31.51%	32.90%	43.13%	36.84%
EBITDA Margin	-27.62%	-24.00%	-28.77%	11.96%	50.33%	37.91%	-25.79%	-43.32%	47.90%	-11.38%	-24.71%
Operating Margin	-36.06%	-37.96%	-41.15%	-33.85%	8.19%	-18.05%	-44.79%	-38.25%	31.68%	-25.81%	-41.08%
EBIT Margin	-42.53%	-38.45%	-43.94%	-1.53%	36.20%	24.47%	-41.74%	-60.89%	32.81%	-26.55%	-42.69%
Profit (Net Income) Margin	-47.30%	-36.55%	-47.12%	-5.66%	14.33%	7.64%	-45.09%	-94.66%	14.26%	-21.06%	-44.16%
Tax Burden Percent	107.78%	91.71%	98.38%	97.36%	51.40%	40.09%	92.15%	91.34%	52.21%	66.64%	89.98%
Interest Burden Percent	103.18%	103.64%	109.01%	378.68%	77.04%	77.86%	117.23%	170.21%	83.25%	119.01%	114.96%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	48.59%	59.87%	0.00%	0.00%	47.78%	0.00%	0.00%
Return on Invested Capital (ROIC)	-13.96%	-14.58%	-16.38%	-11.39%	2.09%	-3.65%	-16.19%	-13.20%	8.32%	-8.64%	-13.39%
ROIC Less NNEP Spread (ROIC-NNEP)	-139.89%	-33.17%	-863.97%	118.68%	224.05%	67.02%	-54.85%	-18,755.16%	12.75%	0.82%	168.13%
Return on Net Nonoperating Assets (RNNOA)	-2.85%	-2.20%	-2.31%	2.05%	1.25%	1.88%	-2.28%	-7.91%	-0.74%	-0.03%	-1.41%
Return on Equity (ROE)	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%	-18.46%	-21.12%	7.59%	-8.66%	-14.80%
Cash Return on Invested Capital (CROIC)	-1.53%	-0.09%	-4.96%	7.59%	4.51%	7.01%	-2.33%	-8.48%	2.87%	0.36%	2.61%
Operating Return on Assets (OROA)	-17.23%	-15.89%	-16.96%	-0.53%	11.94%	8.29%	-14.03%	-20.46%	9.91%	-7.80%	-12.45%
Return on Assets (ROA)	-19.15%	-15.10%	-18.18%	-1.96%	4.73%	2.59%	-15.15%	-31.80%	4.31%	-6.18%	-12.88%
Return on Common Equity (ROCE)	-16.80%	-16.78%	-18.69%	-9.34%	3.34%	-1.77%	-18.46%	-21.12%	7.59%	-8.66%	-14.80%
Return on Equity Simple (ROE_SIMPLE)	-14.37%	0.00%	-20.15%	-17.42%	-9.53%	0.00%	-2.97%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-45	-48	-50	-43	7.31	-13	-47	-42	25	-27	-36
NOPAT Margin	-25.24%	-26.57%	-28.81%	-23.70%	4.21%	-7.24%	-31.36%	-26.78%	16.54%	-18.07%	-28.75%
Net Nonoperating Expense Percent (NNEP)	125.94%	18.58%	847.58%	-130.07%	-221.96%	-70.66%	38.67%	18,741.95%	-4.43%	-9.45%	-181.52%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.96%	-	-	-	-0.74%	-2.69%	-2.56%	1.52%	-1.67%	-2.31%
Cost of Revenue to Revenue	73.30%	75.42%	75.78%	71.65%	76.89%	53.90%	71.58%	68.50%	67.10%	56.87%	63.16%
SG&A Expenses to Revenue	40.45%	40.07%	40.40%	37.78%	56.56%	36.50%	39.40%	38.01%	35.47%	34.03%	39.14%
R&D to Revenue	10.88%	10.66%	12.63%	13.22%	16.57%	16.57%	20.57%	19.35%	19.83%	22.08%	23.51%
Operating Expenses to Revenue	62.76%	62.53%	65.37%	62.20%	14.92%	64.15%	73.22%	69.76%	1.21%	68.94%	77.92%
Earnings before Interest and Taxes (EBIT)	-76	-70	-76	-2.80	63	45	-63	-95	50	-39	-53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-49	-44	-50	22	87	70	-39	-68	73	-17	-31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.86	0.84	0.67	0.62	0.74	0.73	0.85	0.81	0.94	0.76	0.72
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	78.49	33.35	40.81	4.18	16.96	13.51	3.62	27.92
Price to Revenue (P/Rev)	1.43	1.35	1.05	1.22	1.46	1.41	1.62	1.58	1.92	1.59	1.49
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.86	0.85	0.78	0.69	0.73	0.72	0.85	0.82	0.94	0.75	0.72
Enterprise Value to Revenue (EV/Rev)	1.53	1.50	1.33	1.29	1.36	1.33	1.60	1.66	1.78	1.53	1.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	62.30	7.38	7.87	21.87	32.06	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	33.16	26.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	8.20	15.02	9.58	0.00	0.00	31.19	204.74	26.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.17	0.17	0.28	0.14	0.31	0.32	0.33	0.26	0.26	0.27	0.29
Long-Term Debt to Equity	0.15	0.15	0.26	0.13	0.30	0.31	0.25	0.25	0.25	0.26	0.28
Financial Leverage	0.02	0.07	0.00	0.02	0.01	0.03	0.04	0.00	-0.06	-0.04	-0.01
Leverage Ratio	1.39	1.42	1.48	1.41	1.51	1.53	1.60	1.47	1.57	1.57	1.58
Compound Leverage Factor	1.44	1.47	1.61	5.35	1.17	1.19	1.88	2.50	1.31	1.87	1.82
Debt to Total Capital	14.42%	14.82%	21.65%	12.44%	23.76%	24.13%	24.97%	20.80%	20.74%	21.23%	22.20%
Short-Term Debt to Total Capital	1.78%	1.67%	1.44%	1.40%	0.73%	0.83%	6.49%	0.86%	0.78%	0.64%	0.62%
Long-Term Debt to Total Capital	12.64%	13.14%	20.21%	11.04%	23.04%	23.29%	18.48%	19.94%	19.97%	20.59%	21.57%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	85.58%	85.18%	78.35%	87.56%	76.24%	75.87%	75.03%	79.20%	79.26%	78.77%	77.80%
Debt to EBITDA	-2.49	-3.54	-2.66	-1.64	28.11	3.37	3.11	6.75	9.58	-6.72	-8.02
Net Debt to EBITDA	-0.87	-1.90	-1.76	-0.46	-4.47	-0.41	-0.09	1.11	-2.44	0.82	0.20
Long-Term Debt to EBITDA	-2.18	-3.14	-2.48	-1.45	27.25	3.25	2.31	6.48	9.22	-6.52	-7.79
Debt to NOPAT	-2.43	-2.20	-2.50	-1.06	-3.32	-4.08	-4.22	-3.33	-4.35	-4.16	-4.85
Net Debt to NOPAT	-0.85	-1.18	-1.66	-0.30	0.53	0.49	0.12	-0.55	1.11	0.51	0.12
Long-Term Debt to NOPAT	-2.13	-1.95	-2.33	-0.94	-3.22	-3.94	-3.12	-3.19	-4.19	-4.03	-4.71
Altman Z-Score	0.28	0.10	-0.40	-0.15	0.07	0.05	-0.11	-0.26	0.16	-0.27	-0.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.78	1.55	1.92	1.63	2.97	3.43	2.49	3.41	3.70	3.97	3.61
Quick Ratio	1.28	0.62	0.92	0.66	2.42	2.85	1.80	2.17	3.01	0.62	0.54
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	31	60	19	257	203	192	25	-54	140	60	68
Operating Cash Flow to CapEx	787.75%	-2,700.56%	-800.50%	-366.29%	-971.14%	-831.63%	-1,105.02%	-2,632.38%	0.00%	-12.94%	-1,072.78%
Free Cash Flow to Firm to Interest Expense	9.21	17.41	2.44	31.37	11.72	13.51	1.64	-0.77	12.35	5.29	6.19
Operating Cash Flow to Interest Expense	9.78	-11.09	-4.63	-3.23	-4.44	-3.12	-2.23	-1.19	-3.05	-2.29	-1.77
Operating Cash Flow Less CapEx to Interest Expense	8.54	-11.50	-5.21	-4.11	-4.90	-3.49	-2.44	-1.23	14.09	-20.00	-1.93
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.41	0.39	0.35	0.33	0.34	0.34	0.34	0.30	0.29	0.29
Accounts Receivable Turnover	7.21	6.89	6.87	4.53	6.35	5.91	6.64	6.49	6.38	5.83	6.61
Inventory Turnover	7.66	7.80	7.99	7.92	8.30	8.08	7.63	7.07	6.68	6.54	5.80
Fixed Asset Turnover	0.00	10.91	11.03	9.84	9.46	9.80	10.19	9.37	8.72	8.43	8.08
Accounts Payable Turnover	9.22	7.98	7.10	6.23	8.23	8.47	7.21	6.44	7.32	9.09	7.19
Days Sales Outstanding (DSO)	50.66	52.98	53.15	80.58	57.47	61.78	54.93	56.26	57.18	62.63	55.21
Days Inventory Outstanding (DIO)	47.67	46.77	45.66	46.08	43.97	45.20	47.87	51.62	54.62	55.81	62.98
Days Payable Outstanding (DPO)	39.57	45.73	51.38	58.55	44.36	43.08	50.65	56.69	49.87	40.14	50.79
Cash Conversion Cycle (CCC)	58.75	54.02	47.43	68.11	57.08	63.90	52.16	51.19	61.93	78.31	67.40
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,530	1,519	1,372	1,341	1,334	1,313	1,299	1,353	1,219	1,226	1,196
Invested Capital Turnover	0.55	0.55	0.57	0.48	0.50	0.50	0.52	0.49	0.50	0.48	0.47
Increase / (Decrease) in Invested Capital	-76	-108	-69	-300	-196	-206	-72	12	-115	-87	-103
Enterprise Value (EV)	1,322	1,297	1,066	927	970	951	1,102	1,103	1,144	926	857
Market Capitalization	1,237	1,167	836	871	1,039	1,003	1,115	1,047	1,230	967	865
Book Value per Share	$1.87	$1.80	$1.80	$2.00	$2.01	$2.00	$1.95	$1.64	$1.64	$1.65	$1.59
Tangible Book Value per Share	($0.13)	($0.19)	($0.22)	$0.02	$0.04	$0.04	$0.40	$0.08	$0.11	$0.35	$0.04
Total Capital	1,688	1,631	1,599	1,594	1,841	1,800	1,748	1,637	1,647	1,610	1,548
Total Debt	243	242	346	198	437	434	436	341	342	342	344
Total Long-Term Debt	213	214	323	176	424	419	323	326	329	331	334
Net Debt	85	130	229	56	-70	-52	-12	56	-87	-42	-8.74
Capital Expenditures (CapEx)	4.20	1.42	4.44	7.22	7.94	5.34	3.13	3.17	-195	200	1.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)	48	41	134	120	25	52	119	154	55	76	55
Debt-free Net Working Capital (DFNWC)	187	137	210	161	431	484	555	426	471	445	397
Net Working Capital (NWC)	157	109	187	138	418	469	442	412	458	435	387
Net Nonoperating Expense (NNE)	39	18	32	-33	-18	-27	21	106	3.46	4.44	19
Net Nonoperating Obligations (NNO)	85	130	119	-55	-70	-52	-12	56	-87	-42	-8.74
Total Depreciation and Amortization (D&A)	27	26	26	25	25	25	24	28	23	23	22
Debt-free, Cash-free Net Working Capital to Revenue	5.56%	4.73%	16.80%	16.77%	3.51%	7.30%	17.28%	23.26%	8.63%	12.59%	9.42%
Debt-free Net Working Capital to Revenue	21.55%	15.83%	26.26%	22.44%	60.64%	67.87%	80.52%	64.18%	73.29%	73.40%	68.25%
Net Working Capital to Revenue	18.07%	12.67%	23.38%	19.32%	58.75%	65.76%	64.08%	62.07%	71.30%	71.71%	66.59%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.11)	($0.09)	($0.12)	($0.01)	$0.04	$0.01	($0.10)	($0.19)	$0.03	($0.04)	($0.07)
Adjusted Weighted Average Basic Shares Outstanding	751.53M	751.77M	706.88M	697.21M	694.62M	694.02M	671.58M	788.01M	777.15M	751.13M	758.88M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.03	$0.00	$0.00	($0.19)	$0.03	$0.00	($0.07)
Adjusted Weighted Average Diluted Shares Outstanding	773.06M	696.99M	696.99M	697.38M	998.36M	671.55M	793.05M	788.01M	779.92M	751.13M	758.88M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	773.06M	696.99M	696.99M	697.38M	682.48M	671.55M	793.05M	793.78M	767.70M	759.07M	755.09M
Normalized Net Operating Profit after Tax (NOPAT)	-46	-48	-50	-43	7.31	-108	-47	-42	-28	-27	-36
Normalized NOPAT Margin	-25.69%	-26.57%	-28.81%	-23.70%	4.21%	-58.94%	-31.36%	-26.78%	-18.43%	-18.07%	-28.75%
Pre Tax Income Margin	-43.89%	-39.85%	-47.89%	-5.81%	27.89%	19.05%	-48.93%	-103.64%	27.32%	-31.59%	-49.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-22.45	-20.25	-9.93	-0.34	3.62	3.16	-4.05	-1.36	4.38	-3.48	-4.85
NOPAT to Interest Expense	-13.32	-13.99	-6.51	-5.28	0.42	-0.93	-3.04	-0.60	2.21	-2.37	-3.26
EBIT Less CapEx to Interest Expense	-23.69	-20.66	-10.51	-1.22	3.16	2.78	-4.25	-1.40	21.52	-21.20	-5.01
NOPAT Less CapEx to Interest Expense	-14.57	-14.40	-7.09	-6.16	-0.04	-1.31	-3.24	-0.64	19.35	-20.08	-3.43
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-169.52%	-103.13%	-33.01%	-27.72%	-20.84%	-24.33%

Financials Breakdown Chart

Key Financial Trends

OPKO Health (OPK) has shown a mix of quarterly results over the last several years. The latest Q4 2025 report features a net loss, while the prior Q3 2025 quarter delivered a positive earnings print and notable cash inflows from asset sales. Below are the most relevant trends drawn from OPKO’s quarterly statements across the last four years for retail investors to consider.

Positive quarterly net income in Q3 2025: Consolidated net income / loss was about $21.63 million in Q3 2025 (positive), marking a notable turn from several negative quarters. EPS was +0.03 basic and diluted.
Substantial cash inflow from investing activities in Q3 2025: Net cash from investing activities was about $194.65 million, supported by large asset sales (e.g., PPE and investments).
Solid quarterly cash increase in Q3 2025: Net change in cash and equivalents rose by about $147.05 million in Q3 2025, helping to bolster liquidity for the quarter.
Positive earnings per share in Q3 2025: Basic and diluted earnings per share were both +$0.03 in Q3 2025, indicating quarterly profitability on a per-share basis.
Revenue levels relatively stable around $150–$160 million in 2025: Quarterly operating revenue in 2025 has generally stayed in the ~$150–$160 million range, indicating topline stability versus the more volatile swings in earnings and cash flow.
Asset and liability base appears stable across 2025 (Total assets near $1.996B; Total liabilities around $0.69B): The balance sheet shows a consistent asset base with roughly $1.996B in total assets and liabilities around $690M, suggesting a relatively steady capital structure.
Debt level remains steady (long-term debt around $329M): Long-term debt sits in the mid-$300 million range across 2025, showing continued leverage but no rapidly rising debt load in the period.
Frequent quarterly net losses in 2025: Q2 2025 net income was about -$148.44 million, and Q1 2025 was around -$67.61 million, with Q4 2025 at -$31.26 million, indicating ongoing net-loss pressures outside the standout Q3 print.
Operating cash flow remains negative in most quarters: Net cash from continuing operating activities was negative in several 2025 quarters (e.g., Q4 -$25.9M; Q3 -$34.6M; Q2 -$83.4M; Q1 -$34.6M), highlighting ongoing cash burn from core operations.
Negative earnings per share in multiple periods: In several quarters, including Q4 2025 and earlier quarters, EPS was negative (e.g., Q4 2025 basic EPS -$0.04; Q2 2025 basic EPS -$0.19; Q1 2025 basic EPS -$0.19), signaling persistent profitability challenges outside exceptional quarters.

05/07/26 12:35 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About OPKO Health's Financials

When does OPKO Health's financial year end?

According to the most recent income statement we have on file, OPKO Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has OPKO Health's net income changed over the last 10 years?

OPKO Health's net income appears to be on a downward trend, with a most recent value of -$225.68 million in 2025, rising from -$31.43 million in 2015. The previous period was -$53.22 million in 2024. Check out OPKO Health's forecast to explore projected trends and price targets.

What is OPKO Health's operating income?

OPKO Health's total operating income in 2025 was -$117.41 million, based on the following breakdown:

Total Gross Profit: $205.94 million
Total Operating Expenses: $323.35 million

How has OPKO Health's revenue changed over the last 10 years?

Over the last 10 years, OPKO Health's total revenue changed from $491.74 million in 2015 to $606.88 million in 2025, a change of 23.4%.

How much debt does OPKO Health have?

OPKO Health's total liabilities were at $663.99 million at the end of 2025, a 20.5% decrease from 2024, and a 19.0% decrease since 2015.

How much cash does OPKO Health have?

In the past 10 years, OPKO Health's cash and equivalents has ranged from $0.00 in 2023 to $431.94 million in 2024, and is currently $369.07 million as of their latest financial filing in 2025.

How has OPKO Health's book value per share changed over the last 10 years?

Over the last 10 years, OPKO Health's book value per share changed from 3.63 in 2015 to 1.65 in 2025, a change of -54.5%.

Related Companies

Financial statements for NASDAQ:OPK last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About OPKO Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Financials

Annual Income Statements for OPKO Health

Quarterly Income Statements for OPKO Health

Annual Cash Flow Statements for OPKO Health

Quarterly Cash Flow Statements for OPKO Health

Annual Balance Sheets for OPKO Health

Quarterly Balance Sheets for OPKO Health

Annual Metrics And Ratios for OPKO Health

Quarterly Metrics And Ratios for OPKO Health

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About OPKO Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools